Importantly, we found that the effect of IFNβ on inflammatory MG suppression and anti-inflammatory MG promotion was abrogated in delayed tPA-treated MCAO mice with MG-specific IFNAR1 deletion. The gene discussed is IFNAR1; the disease is myasthenia gravis.